Neuropathic Pain - Pipeline Review, H2 2017

  • ID: 4446945
  • Drug Pipelines
  • 488 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • BCN Peptides SA
  • Develco Pharma Schweiz AG
  • Intec Pharma Ltd
  • Medy-Tox Inc
  • Pharmaleads SA
  • MORE
Neuropathic Pain - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 24, 29, 1, 114, 27 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • BCN Peptides SA
  • Develco Pharma Schweiz AG
  • Intec Pharma Ltd
  • Medy-Tox Inc
  • Pharmaleads SA
  • MORE
Introduction

Neuropathic Pain - Overview

Neuropathic Pain - Therapeutics Development

Neuropathic Pain - Therapeutics Assessment

Neuropathic Pain - Companies Involved in Therapeutics Development

Neuropathic Pain - Drug Profiles

Neuropathic Pain - Dormant Projects

Neuropathic Pain - Discontinued Products

Neuropathic Pain - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Neuropathic Pain, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products under Development by Companies, H2 2017 (Contd..3), H2

Number of Products under Development by Companies, H2 2017 (Contd..4), H2

Number of Products under Development by Companies, H2 2017 (Contd..5), H2

Number of Products under Development by Companies, H2 2017 (Contd..6), H2

Number of Products under Development by Companies, H2 2017 (Contd..7), H2

Number of Products under Development by Universities/Institutes, H2

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Products under Development by Companies, H2 2017 (Contd..4), H2

Products under Development by Companies, H2 2017 (Contd..5), H2

Products under Development by Companies, H2 2017 (Contd..6), H2

Products under Development by Companies, H2 2017 (Contd..7), H2

Products under Development by Companies, H2 2017 (Contd..8), H2

Products under Development by Companies, H2 2017 (Contd..9), H2

Products under Development by Companies, H2 2017 (Contd..10), H2

Products under Development by Companies, H2 2017 (Contd..11), H2

Products under Development by Universities/Institutes, H2

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Target, H2 2017 (Contd..2), H2

Number of Products by Stage and Target, H2 2017 (Contd..3), H2

Number of Products by Stage and Target, H2 2017 (Contd..4), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2

Neuropathic Pain - Pipeline by AbbVie Inc, H2

Neuropathic Pain - Pipeline by Abide Therapeutics Inc, H2

Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H2

Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H2

Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2

Neuropathic Pain - Pipeline by AnaBios Corp, H2

Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H2

Neuropathic Pain - Pipeline by AngioChem Inc, H2

Neuropathic Pain - Pipeline by Aptinyx Inc, H2

Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H2

Neuropathic Pain - Pipeline by Astellas Pharma Inc, H2

Neuropathic Pain - Pipeline by AstraZeneca Plc, H2

Neuropathic Pain - Pipeline by Aucta Pharmaceuticals LLC, H2

Neuropathic Pain - Pipeline by BCI Pharma, H2

Neuropathic Pain - Pipeline by BCN Peptides SA, H2

Neuropathic Pain - Pipeline by Biogen Inc, H2

Neuropathic Pain - Pipeline by Bionomics Ltd, H2

Neuropathic Pain - Pipeline by Bristol-Myers Squibb Co, H2

Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H2

Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H2

Neuropathic Pain - Pipeline by Celgene Corp, H2

Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2

Neuropathic Pain - Pipeline by Cerecor Inc, H2

Neuropathic Pain - Pipeline by Chromocell Corp, H2

Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H2

Neuropathic Pain - Pipeline by Colby Pharmaceutical Co, H2

Neuropathic Pain - Pipeline by ConSynance Therapeutics Inc, H2

Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H2

Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H2

Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H2

Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2

Neuropathic Pain - Pipeline by Daiichi Sankyo Co Ltd, H2

Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2

Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H2

Neuropathic Pain - Pipeline by Eisai Co Ltd, H2

List of Figures

Number of Products under Development for Neuropathic Pain, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Top 10 Routes of Administration, H2

Number of Products by Stage and Top 10 Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 2-BBB Medicines BV
  • AbbVie Inc
  • Abide Therapeutics Inc
  • Acadia Pharmaceuticals Inc
  • Achelios Therapeutics Inc
  • Affectis Pharmaceuticals AG
  • AnaBios Corp
  • Anavex Life Sciences Corp
  • AngioChem Inc
  • Aptinyx Inc
  • Arena Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Aucta Pharmaceuticals LLC
  • BCI Pharma
  • BCN Peptides SA
  • Biogen Inc
  • Bionomics Ltd
  • Bristol-Myers Squibb Co
  • Can-Fite BioPharma Ltd
  • Cara Therapeutics Inc
  • Celgene Corp
  • Centrexion Therapeutics Corp
  • Cerecor Inc
  • Chromocell Corp
  • Circuit Therapeutics Inc
  • Colby Pharmaceutical Co
  • ConSynance Therapeutics Inc
  • ContraVir Pharmaceuticals Inc
  • Crinetics Pharmaceuticals Inc
  • Cytogel Pharma LLC
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Develco Pharma Schweiz AG
  • Dompe Farmaceutici SpA
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Endece LLC
  • Evec Inc
  • Genecode AS
  • GL Pharm Tech Corp
  • Glialogix Inc
  • Grunenthal GmbH
  • GT Biopharma Inc
  • GW Pharmaceuticals Plc
  • Hydra Biosciences Inc
  • Immune Pharmaceuticals Inc
  • India Globalization Capital Inc
  • Intec Pharma Ltd
  • Integral Molecular Inc
  • IntelGenx Corp
  • Intellipharmaceutics International Inc
  • Ionis Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • JT Pharmaceuticals Inc
  • Knopp Biosciences LLC
  • Kolon Life Science Inc
  • KPI Therapeutics Inc
  • Lexicon Pharmaceuticals Inc
  • Lohocla Research Corp
  • Mapi Pharma Ltd
  • MD Biosciences GmbH
  • Medifron DBT Co Ltd
  • MEDRx Co Ltd
  • Medy-Tox Inc
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corp
  • Mundipharma International Ltd
  • Nanomerics Ltd
  • Neurim Pharmaceuticals Ltd
  • Neurocentrx Pharma Ltd
  • NeuroCycle Therapeutics GmbH
  • NeurOp Inc
  • Newron Pharmaceuticals SpA
  • Nippon Chemiphar Co Ltd
  • Nippon Zoki Pharmaceutical Co Ltd
  • NoNO Inc
  • Novartis AG
  • Novassay SA
  • Orexigen Therapeutics Inc
  • Orion Corporation
  • Patagonia Pharmaceuticals LLC
  • PeriphaGen Inc
  • Pfizer Inc
  • Pharmaleads SA
  • Phosphagenics Ltd
  • RaQualia Pharma Inc
  • Re-Pharm Ltd
  • Relmada Therapeutics Inc
  • Revance Therapeutics Inc
  • Rottapharm Biotech Srl
  • Saniona AB
  • Scilex Pharmaceuticals Inc
  • Shionogi & Co Ltd
  • Sunovion Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd
  • Theranexus SAS
  • Toray Industries Inc
  • Torrent Pharmaceuticals Ltd
  • Trevena Inc
  • Vertex Pharmaceuticals Inc
  • Virobay Inc
  • VistaGen Therapeutics Inc
  • Vitality Biopharma Inc
  • Yooyoung Pharm Co Ltd
  • Yuhan Corp
  • Yungjin Pharm Co Ltd
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll